STIMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Neuronetics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$1.91+0.02 (+1.33%)
Close on Oct 19, 2026
- Market cap
- $139.68M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2015 to 2025
Gross margin
48.5%−28.1 pts over 5 years
Operating margin
-21.1%+24.2 pts over 5 years
Net margin
-26.1%+29.6 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +99.2% | +31.8% | +24.8% | – | |
| Gross profit | +33.5% | +13.3% | +13.9% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 6.5% | -74.9% | -155.7% | |
| Return on assets | – | -30.7% | -27.6% | |
| Current ratio | – | 4.75 | 2.02 | |
| Debt to equity | – | 1.36 | 2.94 | |
| Net debt to EBITDA | – | 0.67× | -1.35× | |
| Interest coverage | -5.1× | -4.9× | -3.7× | |
| Inventory turnover | – | 3.6× | 17.9× | |
| Capex to revenue | 0.9% | 1.5% | 0.5% | |
| Diluted shares | 0M | 19M | 66M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Neuronetics generated $142.16M from operations and spent $10.26M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$142.16M
Used
$10.26M
Capital expenditure$10.26M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-26.1%
×Asset turnover1.06×
×Equity multiplier5.64×
=Return on equity, FY2025-155.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -26.1% | 1.06× | 5.64× | -155.7% |
| FY2024 | -58.4% | 0.58× | 4.15× | -141.2% |
| FY2023 | -42.3% | 0.61× | 2.55× | -66.2% |
| FY2022 | -57.0% | 0.51× | 1.81× | -52.3% |
| FY2021 | -56.4% | 0.50× | 1.99× | -56.4% |
| FY2020 | -55.7% | 0.55× | 2.44× | -74.9% |
| FY2019 | -46.4% | 0.58× | 1.83× | -48.9% |
| FY2018 | -45.7% | 0.68× | -1.28× | 39.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$39.00M
- Cash generatingOperating cash flow above zero-$20.40M
- Return on assets improvedROA up on the prior year-37.7% → -27.7%
- Earnings backed by cashOperating cash flow above net income-$20.40M vs -$39.00M
- Less leverageLong-term debt to assets fell39.1% → 46.5%
- Better liquidityCurrent ratio rose1.86 → 2.02
- No dilutionShare count did not rise32M → 66M
- Gross margin improvedGross margin up on the prior year72.32% → 48.48%
- More efficientAsset turnover rose0.65 → 1.06